Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021)

Immuneering has reported Preferred Stock Liabilities over the past 2 years, most recently at $82.9 million for Q2 2021.

  • Quarterly results put Preferred Stock Liabilities at $82.9 million for Q2 2021, up 292.49% from a year ago — trailing twelve months through Jun 2021 was $82.9 million (up 292.49% YoY), and the annual figure for FY2020 was $37.0 million, changed.
  • Preferred Stock Liabilities for Q2 2021 was $82.9 million at Immuneering, up from $37.0 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for IMRX hit a ceiling of $82.9 million in Q2 2021 and a floor of $21.1 million in Q2 2020.